US Edition2025 EASL Congress Spotlight: CG-0416 Preclinical Data Unveils A Groundbreaking Dual-Action Therapy Targeting Obesity and MASH
- CureGene Pharmaceuticals announced late-breaking preclinical results for CG-0416 at the 2025 EASL Annual Congress in a Poster session.
- The results follow preclinical studies using 26-week diet-induced obesity murine models combining CG-0416 with low-dose semaglutide due to limits of GLP-1 agonists in muscle preservation and sustained weight control.
- CG-0416 is a novel liver-targeted thyroid hormone receptor beta prodrug that achieves 20-fold higher intrahepatic active metabolite concentrations, reducing hepatic lipids by 58%, improving weight loss by 66%, and halving muscle loss rate.
- The combination treatment achieved a notably lower ratio of muscle loss relative to fat loss—0.18 kilograms of muscle lost per kilogram of fat lost—compared to a range of 0.35 to 0.63 kg/kg observed with current therapies, while CG-0416 exhibited an oral bioavailability of 92%, which is twice that of approved THR-β agents.
- The data highlight CG-0416 as a promising dual-action therapeutic candidate targeting both MASH and obesity, offering enhanced metabolic regulation and a favorable safety profile, while forward-looking statements caution that future results may be influenced by various risks and uncertainties.
Insights by Ground AI
Does this summary seem wrong?
77 Articles
77 Articles
All
Left
9
Center
23
Right
6
The Courier-Tribune+76 Reposted by 76 other sources
2025 EASL Congress Spotlight: CG-0416 Preclinical Data Unveils A Groundbreaking Dual-Action Therapy Targeting Obesity and MASH
——A First-in-Class Hydrolysis-Activated Liver-Targeted THR-β Prodrug Demonstrating A Dual Advantage of Fat Reduction and Muscle Preservation
Coverage Details
Total News Sources77
Leaning Left9Leaning Right6Center23Last UpdatedBias Distribution61% Center
Bias Distribution
- 61% of the sources are Center
61% Center
L 24%
C 61%
R 16%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
